Somewhat Favorable Press Coverage Somewhat Unlikely to Impact La Jolla Pharmaceutical (LJPC) Share Price
News stories about La Jolla Pharmaceutical (NASDAQ:LJPC) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. La Jolla Pharmaceutical earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.1970348331376 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- La Jolla Pharmaceutical Company (NASDAQ: LJPC) – Glistening Stock’s Review – Alpha Beta Stock (alphabetastock.com)
- La Jolla Pharmaceutical (LJPC) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)
- La Jolla Pharmaceutical (LJPC) Fell To Nearly A 6-Month Low (rttnews.com)
- Here’s What to Focus on: La Jolla Pharmaceutical Company … – Alpha Beta Stock (alphabetastock.com)
- JPMorgan Downgrades La Jolla Pharma (LJPC) to Underweight – StreetInsider.com (streetinsider.com)
LJPC has been the topic of several research analyst reports. J P Morgan Chase & Co downgraded La Jolla Pharmaceutical from an “overweight” rating to an “underweight” rating and set a $20.00 price objective on the stock. in a report on Friday, December 8th. Zacks Investment Research upgraded La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a report on Wednesday, November 1st. Cowen reiterated a “buy” rating and issued a $55.00 price objective on shares of La Jolla Pharmaceutical in a report on Friday, October 27th. Jefferies Group reiterated a “buy” rating and issued a $40.00 price objective on shares of La Jolla Pharmaceutical in a report on Tuesday, October 3rd. Finally, ValuEngine downgraded La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $49.33.
Shares of La Jolla Pharmaceutical (NASDAQ LJPC) traded down $1.95 during midday trading on Wednesday, reaching $26.15. The company’s stock had a trading volume of 821,000 shares, compared to its average volume of 455,847. La Jolla Pharmaceutical has a 12 month low of $16.41 and a 12 month high of $39.28.
La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.05. equities analysts expect that La Jolla Pharmaceutical will post -4.93 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact La Jolla Pharmaceutical (LJPC) Share Price” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-la-jolla-pharmaceutical-ljpc-share-price/1761324.html.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.